Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6961)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Nov 28, 2020 (publication date) through Dec 2, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Transplantation
ISSN
2220-3230
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Piñero F, Thompson M, Marín JI, Silva M. Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients? World J Transplant 2020; 10(11): 297-306 [PMID: 33312891 DOI: 10.5500/wjt.v10.i11.297] |
|---|---|
| URL: | https://www.wjgnet.com/2220-315x/full/v10/i11/297.htm |
| Number | Citing Articles |
| 1 |
Yen-Yang Chen, Chao-Long Chen, Chih-Che Lin, Chih-Chi Wang, Yueh-Wei Liu, Wei-Feng Li, Yen-Hao Chen. Efficacy and Safety of Lenvatinib in Hepatocellular Carcinoma Patients with Liver Transplantation: A Case-Control Study. Cancers 2021; 13(18): 4584 doi: 10.3390/cancers13184584
|
| 2 |
Marie Decraecker, Caroline Toulouse, Jean-Frédéric Blanc. Is There Still a Place for Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma at the Time of Immunotherapies? A Focus on Lenvatinib. Cancers 2021; 13(24): 6310 doi: 10.3390/cancers13246310
|
| 3 |
Mehmet Akce, Bassel F. El-Rayes, Tanios S. Bekaii-Saab. Frontline therapy for advanced hepatocellular carcinoma: an update. Therapeutic Advances in Gastroenterology 2022; 15 doi: 10.1177/17562848221086126
|
| 4 |
Jing Liang, Yi Bai, Fu-Shuang Ha, Ying Luo, Hui-Ting Deng, Ying-Tang Gao. Combining local regional therapy and systemic therapy: Expected changes in the treatment landscape of recurrent hepatocellular carcinoma. World Journal of Gastrointestinal Oncology 2023; 15(1): 1-18 doi: 10.4251/wjgo.v15.i1.1
|
| 5 |
Reimi Suzuki, Ryoichi Goto, Norio Kawamura, Masaaki Watanabe, Yoshikazu Ganchiku, Kanako C Hatanaka, Yutaka Hatanaka, Toshiya Kamiyama, Tsuyoshi Shimamura, Akinobu Taketomi. Efficient multiple treatments including molecular targeting agents in a case of recurrent hepatocellular carcinoma, post-living donor liver transplantation. Clinical Journal of Gastroenterology 2022; 15(4): 755 doi: 10.1007/s12328-022-01643-3
|
| 6 |
Kyunghye Bang, Andrea Casadei‐Gardini, Changhoon Yoo, Massimo Iavarone, Min‐Hee Ryu, Sook Ryun Park, Hyung‐Don Kim, Young‐In Yoon, Dong‐Hwan Jung, Gil‐Chun Park, Chul‐Soo Ahn, Deok‐Bog Moon, Shin Hwang, Ki‐Hun Kim, Gi‐Won Song, Chiara Mazzarelli, Eleonora Alimenti, Stephen L. Chan, Massimo De Giorgio, Baek‐Yeol Ryoo, Sung‐Gyu Lee. Efficacy and safety of lenvatinib in patients with recurrent hepatocellular carcinoma after liver transplantation. Cancer Medicine 2023; 12(3): 2572 doi: 10.1002/cam4.5123
|
| 7 |
Filippo Pelizzaro, Martina Gambato, Enrico Gringeri, Alessandro Vitale, Umberto Cillo, Fabio Farinati, Patrizia Burra, Francesco Paolo Russo. Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. Cancers 2021; 13(19): 4882 doi: 10.3390/cancers13194882
|